Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q86WI3
UPID:
NLRC5_HUMAN
Alternative names:
Caterpiller protein 16.1; Nucleotide-binding oligomerization domain protein 27; Nucleotide-binding oligomerization domain protein 4
Alternative UPACC:
Q86WI3; B5MEF1; C9JMD8; Q6P4A6; Q86VM7; Q8NF42; Q8TEE2; Q8TEJ1; Q969L7
Background:
Protein NLRC5, also known as Caterpiller protein 16.1, Nucleotide-binding oligomerization domain protein 27, and Nucleotide-binding oligomerization domain protein 4, is a probable regulator of the NF-kappa-B and type I interferon signaling pathways. It may also influence the type II interferon signaling pathway, playing a pivotal role in the homeostatic control of innate immunity and antiviral defense mechanisms.
Therapeutic significance:
Understanding the role of Protein NLRC5 could open doors to potential therapeutic strategies.